TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of patients progression-free at 12 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Asthma Control Test (ACT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RHINASTHMA Global Summary (GS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage proportion of eosinophils in nasal lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood eosinophil count of less than 600 per microliter for 8 or more consecutive weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median time free of VAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: wake-up times from termination of sedative administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of time within a predefined desired interval on a sedation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Nd:YAG capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of fibrotic PCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 15-letter BCVA gain from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean average BCVA change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean average CRT change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper extremity performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical framework complications
Endpoint domain: Adverse events/effects
Primary endpoint: Bone loss around implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor skill learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in running time in plain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in running time uphill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung injury biomarkers (CC16 and sRAGEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free from local and regional recurrences
Endpoint domain: Mortality/survival
Primary endpoint: complete healing of minor mouth ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ulcer size after 10 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of hunger
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fullness and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decline in CD4 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in CD4+CD25+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in natural killer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients without nephrotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of remission from nephrotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall follow-up rate on key clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability indices improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: secretion of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urinary free cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Abdominal closure success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Initial intra-abdominal pressure (IAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contrast sensitivity after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-item General Health Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: early clinical improvement at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shift of mRS distribution at day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in the perfusion lesion by 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Log-ons to the disease prevention website
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of influenza-like illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall 5-year recurrence-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: improvements in evaporative sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in tactile sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in dentin hypersensitivity (DH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluctuation of CSF Aβ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-assessed competence in screening for social determinants of health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MLP referral rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: formula distribution
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: loco-regional control
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of Weight on Quality of Life-Lite total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 4-year patient survival
Endpoint domain: Mortality/survival
Primary endpoint: 4-year rejection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: spirometry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of drug-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Kitaoka score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Olerud‐Molander score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically relevant POPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: further analgesic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: videogame performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visuospatial working memory (WM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of at least one tophus at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean velocity of resolution of all tophi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing process improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic severity and extent of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: frequency of cannabis and alcohol abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in physical activity (miles per week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mass of 1-OHP excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in skin pad deposition of pyrene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in 1-OHP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of prasugrel or ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effortful control scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean maximal IAP during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total efficacy rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of CK-MB elevation >3 times the normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of angiographic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma levels of fibrinogen and Factor VIIc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: capacity of coagulation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fibrinolytic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fecal calprotectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of dermal structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved medication reconciliation behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of hysteroscopy in diagnosing endometrial polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of hysteroscopy in diagnosing submucous myomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of blind biopsy in diagnosing hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in frequency of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean scores of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: lesion size increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new lesions developed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteal phase serum estradiol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hormone levels in the pituitary-ovarian axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in symptoms (NYHA class)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced number of cardiac events (death plus heart transplantation)
Endpoint domain: Mortality/survival
Primary endpoint: comprehension score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: subjective understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall satisfaction with consent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS score for satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: LS score for ease of use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: biochemical recurrence of prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of hypokalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum potassium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complications risk other than rerupture
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Abstinence from bulimic behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate variability (rMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cup abduction and anteversion angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral offset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative LLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stem alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hip center of rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral stem canal fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in LCQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: subjective ratings of mental slowness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Iron status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: distension fluid deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: menstrual pattern at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: No recollection of the study
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavioral side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Residual urine after voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in gingival inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in microbiological parameters (T. denticola)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hBD-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lipid accumulation product index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of composite complications
Endpoint domain: Adverse events/effects
Primary endpoint: Foot length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: completeness of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcome prediction after SAH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Migraine-Specific Quality of Life (MSQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinically elevated levels of OA pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically elevated levels of insomnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of urticaria episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of urticaria episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of urticaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface EMG potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving metformin and non dose-adjusted DPP-4 inhibitors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients reaching target HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean FPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average daily food expenditure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean posttreatment-to-pretreatment flow rate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: death from disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Surgical Site Infection (SSI) occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Contribution margin
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage agreement for clinical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Severe sleep disturbance
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Corneal endothelial cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final complete anatomical reattachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean visual acuity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormone levels of luteinizing hormone (LH), testosterone (T) and free T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Faster skill acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of failed attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Suture times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Akathisia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital findings (respiration rates, pulse rates, systolic blood pressures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in patients' cooperation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posterior capsule opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100% contrast visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality assessed visually
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart-to-lung, heart-to-liver, and myocardium-to-background ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety (side effects)
Endpoint domain: Adverse events/effects
Primary endpoint: plasma PTH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: inhibitory effect on PTH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Withdrawal for chemotherapy‐induced toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean cisplatin cumulative dose delivered (CDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nephrotoxicity as determined by changes in serum creatinine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: rectal allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rectal hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: plasma 5-HTP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional dose of medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk for development of extrapyramidal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: prevalence of P aeruginosa positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent neointimal hyperplasia mean area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent neointimal hyperplasia mean volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late acquired incomplete stent apposition
Endpoint domain: Adverse events/effects
Primary endpoint: Ejaculation delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definitive clinical and parasitologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes